CONMED Q2 GAAP EPS Up 11.6%, Details Convertible Note Repurchase & Strategic Divestiture
CNMD sits 48% above its 52-week low of $31.44.
Summary
CONMED's Q2 2026 report confirms solid GAAP earnings growth and details significant financial maneuvers, including a large convertible note repurchase, ongoing share buybacks, and the strategic divestiture of its gastroenterology business.
Key Events · Earnings and Guidance · CNMD
-
Q2 2026 Financial Performance
Net income for Q2 2026 was $23.071 million, up 7.7% year-over-year. Basic EPS increased 11.6% to $0.77, and diluted EPS also rose 11.6% to $0.77, compared to Q2 2025.
-
Significant Debt Repurchase
The company repurchased $645.2 million principal amount of its 2.250% convertible notes for $637.2 million in cash. This was funded by a new $450 million Term A-2 Loan and borrowings from the revolving credit facility.
-
Ongoing Share Repurchase Program
CONMED repurchased $43.2 million of common stock during the first six months of 2026. Approximately $106.3 million remains under the $150 million share repurchase program authorized in October 2025.
-
Strategic Divestiture Completed
The sale of additional assets related to the gastroenterology product offerings was completed for $14.0 million, resulting in a $4.4 million loss on sale and a $9.8 million goodwill write-off as part of portfolio optimization.
Analysis · CNMD · Industrial Applications And Services
This quarterly report details CONMED's financial performance for Q2 2026, showing growth in GAAP net income and EPS, aligning with the previously reported adjusted earnings beat. The filing provides the official figures and context for several significant financial and strategic actions. Key among these is the successful repurchase of a substantial portion of convertible notes, which was a major debt management initiative. The company also continued its share repurchase program and completed the strategic divestiture of its gastroenterology product line, which impacted sales but is part of portfolio optimization. A notable one-time benefit came from $10.2 million in IEEPA tariff refunds, boosting gross margins.
At the time of this filing, CNMD was trading at $46.45 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $31.44 to $56.64. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.